ProtAb
Antibody for Treating Autoimmune Disorders
Company Overview
Snapshot
Founded in August 2005 by Yaakov Naparstek, ProtAb operates with 1–10 employees. The company has raised $8.9 million across three funding rounds from three investors. ProtAb is focused on developing therapeutic agents for autoimmune and inflammatory diseases, with its lead product, Prozumab, currently in late-stage preclinical development.
Business overview
ProtAb Ltd develops therapeutic agents that modulate cytokine regulation to promote anti-inflammatory signaling pathways, targeting autoimmune and inflammatory diseases. Its core product, Prozumab, is a monoclonal antibody designed to treat inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA). The company operates within the pharmaceuticals sector, focusing on drug discovery and development in the health tech and life sciences market.
Company Intelligence Q&A
- What is ProtAb's primary focus?
- ProtAb Ltd focuses on developing therapeutic agents that modulate cytokine regulation to shift the balance towards anti-inflammatory signaling pathways, primarily for the treatment of autoimmune and inflammatory diseases.
- What is Prozumab?
- Prozumab is ProtAb's lead product, a monoclonal antibody with a novel mechanism of action. It is currently in late-stage preclinical development for inflammatory bowel disease (IBD), ulcerative colitis (UC), and rheumatoid arthritis (RA).
- Who founded ProtAb?
- ProtAb was founded by Yaakov Naparstek in August 2005.
- How much capital has ProtAb raised in total?
- ProtAb has raised a total of $8.9 million across three funding rounds.
- Which investors participated in ProtAb's April 2010 funding round?
- In April 2010, ProtAb received funding from Hadasit Bio-Holdings and Clal Biotechnology Industries (CBI).